Ready to transform your health
Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide in Ozempic and Wegovy) and the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) work by mimicking naturally occurring hormones that regulate blood glucose and appetite
Exploring Injectable Therapies for Weight Loss and Diabetes Management: GLP-1, Ozempic, Wegovy, and Trulicity The global prevalence of obesity and diabetes continues to rise unabated, posing significant challenges to public health worldwide
[9] The programs mix of healthy habit tracking, community support, and brand-name GLP-1 medications helps people lose weight and keep it off, especially if they stay active in the app and follow their coachs guidance
They show up at 9:47 p.m
Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration